查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496012

全球黃斑部病變檢測與治療市場：2024-2029 年預測

Global Macular Degeneration Testing and Therapeutics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

黃斑部病變檢測和治療市場預計將從 2022 年的 118.32 億美元增至 2029 年的 149.59 億美元，預測期內複合年成長率為 3.42%。

黃斑部病變檢測和治療是針對這種常見眼科疾病的診斷和治療方法，這種疾病會影響黃斑，黃斑部是視網膜的中央部分，負責敏銳的中央視力。黃斑部病變有兩種主要類型：乾性（萎縮性）和濕性（新生血管性或滲出性）。檢驗包括視力檢查、散瞳驗光、螢光血管造影術、光同調斷層掃瞄(OCT) 和基因檢測。

黃斑部病變檢測和治療市場包括旨在檢測、監測和提供有效治療方案的診斷工具、藥品、補充品和醫療設備。診斷工具包括OCT機、眼底攝影機、螢光血管造影術系統、抗VEGF藥物、補充品、眼內植入、低視力輔助器具、基因檢測服務等。人口老化、診斷影像技術的進步以及對新治療方法的持續研究正在推動市場發展。

市場促進因素：

  • 隨著研究和開發活性化，黃斑部病變檢測和治療市場預計將成長。

擴大研發力度和增加臨床試驗是產業成長的關鍵驅動力。研究和開發活動預計將推動黃斑部病變檢測和治療行業的發展。這包括擴大創造性的治療方法，包括高品質的基因療法、幹細胞療法和聯合療法。發現的治療進展和生物標記的進步正在促進早期檢測和個人化治療。先進的藥物輸送框架正在開發中，包括新配方和緩釋性植入。

此外，臨床試驗也已開始，以確保新藥和治療方法的商業化。這些努力預計將導致黃斑部病變新藥獲得監管部門的核准和商業化。例如，2022年11月，專注於基因治療藥物的臨床階段生物技術公司4D Molecular Therapeutics宣布，專注於基因治療藥物的臨床階段生物技術公司4D Molecular Therapeutics, Inc.宣布4D Molecular Therapeutics、 Inc.是一家專門從事基因治療藥物的臨床階段生物技術公司，宣布推出用於治療濕性老齡化黃斑部病變（AMD）的玻璃體內4D-150 I/II期藥物。 。

  • 視網膜疾病的日益普及預計將推動黃斑部病變檢測和治療市場的成長。

由於老齡化黃斑部病變(AMD) 的盛行率不斷增加，黃斑部病變檢測和治療行業正在不斷擴大，老年黃斑部病變是視力障礙的根本原因，尤其是在發展中人群中。促成這項進展的因素包括世界人口老化、導致營養不良的不良飲食習慣、肥胖、吸煙和飲酒等生活習慣、OCT等經驗技術的進步以及眼部健康和篩檢的進步。性的認知。

視網膜疾病的增加趨勢正在促進產業的發展。例如，《英國眼科雜誌》2020 年 8 月的一項研究指出，AMD 是歐洲視力障礙和喪失的主要原因。歐洲約有6,700萬人受到AMD的影響，由於世界老年人口的擴大，預計到2050年這數字將大幅增加至15%。這些資料凸顯了受視網膜疾病影響的人數不斷增加，特別是黃斑部病變治療的需求不斷成長。

北美地區預計將佔據市場佔有率。

北美市場參與企業面臨著多種因素，包括老年人口的增加和老齡化黃斑部病變的普遍存在，以及主要行業參與者的進入以及透過市場參與企業和學術研究機構之間的合作夥伴關係擴大研發活動。例如，2020 年 8 月發表在《自然醫學》上的一項研究發現，如果 AMD 患者感染了 SARS-CoV-2，他們更有可能出現嚴重的併發症，包括需要氧療，這一點已經很明確，可能會危及生命。

先進的醫療系統、創新技術的研究、醫療投資的增加、政府活動、患者意識和學術研究促進了黃斑部病變檢測和治療產業的發展。政府措施、政策和臨床試驗可以為AMD的早期檢測和控制提供支援。總的來說，這些因素將有助於未來幾年北美現代治療方法的進步和商業化。

美國黃斑部病變基金會 (AMDF) 發布此資料是為了提醒 AMD 患者和眼部保健專業人員注意潛在風險。 AMD 是全球不可逆視力障礙和視覺障礙的主要原因，並為該行業的成長做出了貢獻。根據加拿大眼科學會2021年2月的訊息，濕性AMD是65歲以上族群視力喪失的重要原因之一。此外，根據加拿大大型企業聯合會的訊息，評估視力喪失的費用預計將從 2007 年的 158 億加元躍升至 2032 年的 303 億加元。

市場發展：

  • 2024 年 3 月 - REGENXBIO 宣布一項 I/IIa 期研究，評估 ABBV-RGX-314 作為濕性AMD的一次性基因療法。這項研究發現，這種治療有可能成為標準治療選擇，維持長期視力健康，並克服長期注射抗 VEGF 治療濕性AMD的臨床挑戰。
  • 2023 年 8 月 - 加州大學戴維斯分校眼科中心使用實驗性基因療法治療濕性老齡化黃斑部病變。該治療是評估 ABBV-RGX-314 有效性和安全性的 3 期臨床試驗的一部分，也是參與該試驗的 93 個美國站點之一。
  • 2022 年 11 月 - IVERIC Bio, Inc. 已開始向美國食品藥物管理局(FDA) 提交新藥認證申請 (NDA) 的初始部分，用於 avacincapad pegol，這是一種新的在臨床實驗補體 C5 抑制劑。
  • 2022 年 11 月 - 歐盟委員會授予歐洲第三種雷珠單抗生物相似藥 Ximluci 的行銷核准。它由 STADA Arzneimittel 和 Xbrane Biopharma 共同開發，將於 2023 年初上市。

公司產品

  • Lee Numbers(R) 低視力手冊 - Lee Numbers(R) 低視力手冊是 Goodlight 公司的產品，專為測試嚴重視力障礙兒童和個人而設計，涵蓋遠端視力和近距離視力線尺寸。它們可以單獨購買，也可以成套購買，其中包括兒童和成人鉸接眼鏡。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球黃斑部病變檢測與治療市場：按類型

  • 介紹
  • 萎縮型
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 滲出型
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球黃斑部病變檢測與治療市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按國家/地區

第7章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第8章 公司簡介

  • Good-Lite Company
  • Leica Microsystems
  • Optovue, Inc
  • Heidelberg Engineering GmbH
  • Topcon
  • Nano Retina
  • Macuhealth
  • LumiThera, Inc
  • Ellex Medical Lasers
  • Quantel Medical
簡介目錄
Product Code: KSI061612157

The global macular degeneration testing and therapeutics market is anticipated to expand at a CAGR of 3.42% amid the projected period to reach US$14.959 billion by 2029, from US$11.832 billion in 2022.

Macular degeneration testing and therapeutics are diagnostic methods and treatment approaches for the common eye condition, which affects the macula, the central part of the retina responsible for sharp, central vision. There are two main types of macular degeneration: dry (atrophic) and wet (neovascular or exudative). Tests include visual acuity tests, dilated eye exams, fluorescein angiography, optical coherence tomography (OCT), and genetic testing.

The market for macular degeneration testing and therapeutics includes diagnostic tools, pharmaceuticals, supplements, and medical devices designed to detect, monitor, and provide effective treatment options. Diagnostic tools include OCT machines, fundus cameras, fluorescein angiography systems, anti-VEGF drugs, supplements, intraocular implants, low vision aids, and genetic testing services. The market is driven by an aging population, advances in diagnostic imaging technology, and ongoing research into novel therapeutic approaches.

Market Drivers:

  • Increasing research and development is expected to surge the macular degeneration testing and therapeutics market growth.

Expanding R&D endeavors and a rise in clinical trials characterized critical drivers of industry growth. R&D practices are anticipated to boost the macular degeneration testing and therapeutics industry. This incorporates expanding inventive therapeutic approaches, quality gene treatments, stem cell treatments, and combination treatments. Progressions in discovery and advancements in biomarkers empower early detection and personalized treatment. Progressed medication delivery frameworks are being created, involving novel formulations and sustained-release implants.

Additionally, Clinical trials are being started to guarantee the commercialization of new medicines and therapies These endeavors are anticipated to lead to regulatory bodies endorsements and the commercialization of new medications for macular degeneration. For instance, in November 2022, 4D Molecular Therapeutics, Inc., a clinical-stage biotechnology company specializing in focused on genetic medications, reported interim clinical discoveries from the Phase I/II trial of intravitreal 4D-150 for wet age-related macular degeneration (AMD).

  • The rising predominance of retinal disorders is anticipated to propel the macular degeneration testing and therapeutics market growth.

The macular degeneration testing and therapeutics industry is expanding due to the increasing prevalence of age-related macular degeneration (AMD), a basic cause of vision inability, particularly inside the developing masses. Factors contributing to this advancement incorporate the worldwide aging populace, lifestyle habits such as poor diet causing malnutrition, obese population, smoking, and drinking, strides in demonstrative technological advancements such as OCT, and extended awareness around the significance of eye wellbeing and screening programs.

The growing predominance of retinal disorders is contributing to industry development. For instance, research in August 2020 by the British Journal of Ophthalmology stated that AMD is the primary factor of visual incapacity and visual loss in Europe. Around 67 million individuals in Europe are influenced by AMD, and this figure is expected to increase significantly to 15% by 2050 due to the expanding elderly population globally. These statistical data emphasize the rising number of people affected by retinal diseases, which particularly interfaces with the extended request for macular degeneration treatment and in this way drives market extension.

The North American area is expected to dominate the market share.

Market expansion in North America is driven by different components, like the increasing senior population and the predominance of age-related macular degeneration, in conjunction with the participation of key industry players and expanded R&D activities with the partnership of market players and academic research institutes. For instance, research published in Nature Medicine in August 2020 revealed that individuals with AMD who contract SARS-CoV-2 confront a higher chance of serious complications, involving requiring supplemental oxygen or can be fatal too.

The country's progressed healthcare framework, investigations for innovative technology, rising healthcare investment, government activities, awareness among patients, and academic research contribute to the macular degeneration testing and therapeutics industry expansion. Government initiatives and policies as well as clinical trials can offer assistance to identify and control AMD at an early stage. Generally, these components contribute to the advancement and commercialization of modern treatments in North America in the years ahead.

The American Macular Degeneration Foundation (AMDF) dispersed this data to alert both AMD patients and eye care experts about the potential risks involved. AMD is a driving main cause of irreversible visual impairment and visual disability universally, contributing to industry growth. According to information from the Canadian Ophthalmological Society from February 2021, wet AMD positions among the essential causes of vision loss in people aged over 65. Moreover, information from the Conference Board of Canada expressed that the evaluated cost of vision loss is projected to surge up to $30.3 billion by 2032 from $15.8 billion in the year 2007.

Market Developments:

  • March 2024- REGENXBIO published a Phase I/IIa study evaluating ABBV-RGX-314 as a one-time gene therapy for wet AMD. The study found that the treatment could become a standard-of-care option, sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to chronic anti-VEGF injections. Long-term follow-up data showed stable or improved vision for up to four years.
  • August 2023- UC Davis Eye Center used experimental gene therapy for wet age-related macular degeneration, marking the first time the center employed such a treatment. The treatment is part of a stage 3 clinical trial assessing the adequacy and security of ABBV-RGX-314, one of 93 U.S. destinations participating in the experiment.
  • November 2022- IVERIC Bio, Inc. initiated the submission of the initial portion of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for avacincaptad pegol, a new investigational inhibitor of complement C5. This accommodation marks the start of a rolling survey to prepare for the treatment of geographic atrophy (GA) auxiliary to Age-Related Macular Degeneration (AMD).
  • November 2022- Marketing authorization was granted by the European Commission for Ximluci, the third biosimilar of ranibizumab, to be approved in the European Union. Created through the collaboration between STADA Arzneimittel and Xbrane Biopharma, the product was discharged to market in early 2023.

Company Product:

  • LEA NUMBERS(R) Low Vision Book- The LEA NUMBERS(R) Low Vision book is a product by Good-Lite Company and is designed for testing severely visually impaired children and adults, covering distance and near vision line sizes. It can be purchased individually or as part of a set, including pediatric and adult occluding glasses.

Market Segmentation:

Global Macular Degeneration Testing and Therapeutics Market is segmented and analyzed as below:

By Type

  • Dry
  • Wet

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL MACULAR DEGENERATION TESTING AND THERAPEUTICS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Dry
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Wet
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL MACULAR DEGENERATION TESTING AND THERAPEUTICS MARKET BY GEOGRAPHY

  • 6.1. Introduction
  • 6.2. North America
    • 6.2.1. By Type
    • 6.2.2. By Country
      • 6.2.2.1. USA
        • 6.2.2.1.1. Market Opportunities and Trends
        • 6.2.2.1.2. Growth Prospects
      • 6.2.2.2. Canada
        • 6.2.2.2.1. Market Opportunities and Trends
        • 6.2.2.2.2. Growth Prospects
      • 6.2.2.3. Mexico
        • 6.2.2.3.1. Market Opportunities and Trends
        • 6.2.2.3.2. Growth Prospects
  • 6.3. South America
    • 6.3.1. By Type
    • 6.3.2. By Country
      • 6.3.2.1. Brazil
        • 6.3.2.1.1. Market Opportunities and Trends
        • 6.3.2.1.2. Growth Prospects
      • 6.3.2.2. Argentina
        • 6.3.2.2.1. Market Opportunities and Trends
        • 6.3.2.2.2. Growth Prospects
      • 6.3.2.3. Others
        • 6.3.2.3.1. Market Opportunities and Trends
        • 6.3.2.3.2. Growth Prospects
  • 6.4. Europe
    • 6.4.1. By Type
    • 6.4.2. By Country
      • 6.4.2.1. United Kingdom
        • 6.4.2.1.1. Market Opportunities and Trends
        • 6.4.2.1.2. Growth Prospects
      • 6.4.2.2. Germany
        • 6.4.2.2.1. Market Opportunities and Trends
        • 6.4.2.2.2. Growth Prospects
      • 6.4.2.3. France
        • 6.4.2.3.1. Market Opportunities and Trends
        • 6.4.2.3.2. Growth Prospects
      • 6.4.2.4. Italy
        • 6.4.2.4.1. Market Opportunities and Trends
        • 6.4.2.4.2. Growth Prospects
      • 6.4.2.5. Others
        • 6.4.2.5.1. Market Opportunities and Trends
        • 6.4.2.5.2. Growth Prospects
  • 6.5. Middle East and Africa
    • 6.5.1. By Type
    • 6.5.2. By Country
      • 6.5.2.1. Saudi Arabia
        • 6.5.2.1.1. Market Opportunities and Trends
        • 6.5.2.1.2. Growth Prospects
      • 6.5.2.2. Israel
        • 6.5.2.2.1. Market Opportunities and Trends
        • 6.5.2.2.2. Growth Prospects
      • 6.5.2.3. Others
        • 6.5.2.3.1. Market Opportunities and Trends
        • 6.5.2.3.2. Growth Prospects
  • 6.6. Asia Pacific
    • 6.6.1. By Type
    • 6.6.2. By Country
      • 6.6.2.1. China
        • 6.6.2.1.1. Market Opportunities and Trends
        • 6.6.2.1.2. Growth Prospects
      • 6.6.2.2. Japan
        • 6.6.2.2.1. Market Opportunities and Trends
        • 6.6.2.2.2. Growth Prospects
      • 6.6.2.3. India
        • 6.6.2.3.1. Market Opportunities and Trends
        • 6.6.2.3.2. Growth Prospects
      • 6.6.2.4. South Korea
        • 6.6.2.4.1. Market Opportunities and Trends
        • 6.6.2.4.2. Growth Prospects
      • 6.6.2.5. Indonesia
        • 6.6.2.5.1. Market Opportunities and Trends
        • 6.6.2.5.2. Growth Prospects
      • 6.6.2.6. Thailand
        • 6.6.2.6.1. Market Opportunities and Trends
        • 6.6.2.6.2. Growth Prospects
      • 6.6.2.7. Taiwan
        • 6.6.2.7.1. Market Opportunities and Trends
        • 6.6.2.7.2. Growth Prospects
      • 6.6.2.8. Others
        • 6.6.2.8.1. Market Opportunities and Trends
        • 6.6.2.8.2. Growth Prospects

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 7.1. Major Players and Strategy Analysis
  • 7.2. Market Share Analysis
  • 7.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 7.4. Competitive Dashboard

8. COMPANY PROFILES

  • 8.1. Good-Lite Company
  • 8.2. Leica Microsystems
  • 8.3. Optovue, Inc
  • 8.4. Heidelberg Engineering GmbH
  • 8.5. Topcon
  • 8.6. Nano Retina
  • 8.7. Macuhealth
  • 8.8. LumiThera, Inc
  • 8.9. Ellex Medical Lasers
  • 8.10. Quantel Medical